Last updated: April 24, 2026
Who supplies crizotinib (drug substance and key components) for pharma use?
Crizotinib supply typically breaks into (1) crizotinib API sourcing (drug substance) and (2) process and key chemical intermediates (for internal manufacture or contract manufacturing). This answer provides a structured supplier map at the API and intermediate level, focused on firms that are commercially positioned in small-molecule oncology supply chains.
What are the core crizotinib supply categories?
- Crizotinib API manufacturers (drug substance)
- Market participants that submit crizotinib to regulatory systems and/or sell via pharma distribution channels.
- Crizotinib intermediate suppliers (for synthesis)
- Providers of upstream building blocks used to assemble crizotinib in common synthetic routes (intermediate handling, purification, and stereochemical/heteroaryl coupling controls depend on route).
Crizotinib API suppliers (drug substance)
Which companies are active crizotinib API suppliers?
Crizotinib API is widely sourced globally. The most consistently referenced and commercially active API participants in oncology tyrosine kinase inhibitor supply chains include:
| Supplier (company) |
Likely supply scope |
Supply positioning (typical) |
Notes |
| Cipla |
API and finished-dose routes |
Branded/generic oncology supply chain |
Large-scale small-molecule supplier; active in global generics. |
| Hetero Drugs |
API and generics |
Oncology generic platform |
Produces and sells small-molecule oncology products at scale. |
| Aurobindo Pharma |
API and finished doses |
Global generics and API |
Large API footprint across oncology. |
| Teva |
Finished doses and API sourcing |
Global commercial supply |
Often supplies via internal and external sourcing networks. |
| Natco Pharma |
API and finished doses |
Oncology generic platform |
Strong in oncology launches and supply. |
| Synthon |
API and finished doses |
European generic platform |
Small-molecule oncology supply presence. |
| Mylan / Viatris |
Finished doses and supply chain |
Global distribution |
Often sources from multi-vendor networks for oncology. |
| Sun Pharma |
API and finished doses |
Global generics |
Large-scale small-molecule oncology supplier. |
Crizotinib intermediate suppliers (key chemicals used in synthesis)
Which intermediate suppliers matter for crizotinib manufacturing?
Intermediate supply for crizotinib depends on the selected synthetic route (heteroaryl formation, amide/amine coupling, late-stage functionalization, and purification). Suppliers in pharma intermediates for small molecules generally include:
| Supplier (company) |
Intermediate scope |
Where they fit in typical synthesis |
Notes |
| TCI Chemicals |
Research and kilo-to-pilot intermediates |
Building blocks and heteroaryl reagents |
Broad catalog; used for route development and some commercial manufacturing runs. |
| Sigma-Aldrich / Merck |
Research and specialty chemicals |
Starting materials and reagents |
Used across medicinal chemistry and pilot production. |
| Bachem |
Specialty intermediates |
Advanced intermediates and derivatization |
Specialty small-molecule intermediary supply in pharma workflows. |
| Alfa Aesar (Thermo Fisher) |
Specialty reagents |
Reagents and building blocks |
Catalog coverage for heteroaryl chemistry. |
| Parchem |
Specialty intermediates |
Custom and distribution |
Regional specialty chemical supply. |
How to source crizotinib safely from a procurement standpoint
What screening gates should pharma buyers apply to crizotinib suppliers?
- Regulatory alignment
- Confirm whether supplier submissions align with target markets (e.g., FDA/EMA pathways for the eventual product).
- Quality systems and documentation
- Request and verify CoA, impurity profile, residual solvent statement, and polymorph data where relevant to the chosen solid form.
- Supply continuity
- Validate vendor capacity, batch lead times, and change control history (especially for oncology API where impurity drift creates regulatory rework).
- Chain-of-custody and audit readiness
- Ensure audit trail for raw materials, intermediates, and final API.
Commercial context: why crizotinib supply is multi-sourced
What market dynamics drive multi-vendor sourcing for crizotinib?
- Oncology demand volatility: crizotinib prescribing depends on ongoing line-of-therapy choices and competitive TKIs.
- API cost structure sensitivity: heteroaryl and late-stage functionalization steps can be yield sensitive, so vendors with higher process yield reduce landed cost.
- Regulatory repeatability: impurity profiles must remain stable across scale-up batches.
Key Takeaways
- Crizotinib supply is typically executed through multi-vendor sourcing: API manufacturers supply drug substance while specialty chemical companies supply key reagents and intermediates used in upstream synthesis.
- The most reliable procurement pattern is to qualify both: (1) API vendors with established regulatory dossiers and (2) intermediate/reagent sources that can support stable impurity and yield outcomes.
- For R&D-to-commercial handoffs, the practical risk is not just “availability,” it is repeatable quality (impurity profile, solid form, residual solvents) under change control.
FAQs
Which type of supplier provides crizotinib API?
API manufacturers supply crizotinib as drug substance; specialty chemical companies typically supply reagents or intermediates rather than full API.
Can pharma buy crizotinib from chemical catalog distributors?
In most cases, catalog distributors sell reagents/intermediates for development. Commercial-scale crizotinib drug substance usually comes from qualified API producers.
What documents should accompany crizotinib API shipments?
Procurement should require CoA, impurity/related substances details, residual solvents, and stability or retest period evidence consistent with the buyer’s quality system.
Why do companies source crizotinib from multiple vendors?
To manage supply continuity and reduce risk from batch-level impurity drift or production disruptions.
What parts of synthesis depend most on vendor control?
Late-stage coupling and heteroaryl assembly steps are typically the most sensitive to yield and impurity formation, so intermediate quality control matters.
References
[1] FDA. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] European Medicines Agency. (n.d.). Medicines. https://www.ema.europa.eu/en/medicines
[3] United States Patent and Trademark Office. (n.d.). Patent Public Search. https://ppubs.uspto.gov/
[4] TCI Chemicals. (n.d.). Product catalog. https://www.tcichemicals.com/
[5] Merck. (n.d.). Sigma-Aldrich product catalog. https://www.sigmaaldrich.com/
